magrolimab + nab-paclitaxel

The combination of magrolimab and nab-paclitaxel is being investigated as a treatment for triple-negative breast cancer (TNBC). This combination therapy is currently in clinical trials, specifically in a Phase 2 randomized study evaluating its safety, tolerability, and efficacy in metastatic TNBC. ## Drug Mechanism and Components Magrolimab is a monoclonal antibody that blocks CD47, a "don't eat me" signal often overexpressed on TNBC cells. By blocking CD47, magrolimab induces macrophage-mediated phagocytosis of tumor cells[1]. This mechanism has shown promising clinical efficacy in hematologic malignancies and is being explored for solid tumors like TNBC. Nab-paclitaxel (also known as albumin-bound paclitaxel or Abraxane) is a cytotoxic agent that stabilizes microtubules in cancer cells and protects them from disassembly, inhibiting normal microtubule network functions essential for cell division[9]. Unlike conventional paclitaxel, nab-paclitaxel utilizes albumin to deliver the taxane, resulting in an advantageous pharmacokinetic profile[6]. The combination therapy leverages potential synergy, as certain chemotherapies like taxanes can enhance prophagocytic signals on tumor cells, which may lead to synergistic antitumor activity with magrolimab[1]. ## Clinical Development The ELEVATE TNBC study (NCT04958785) is evaluating this combination in two cohorts: - **Cohort 1**: Focuses on patients with PD-L1-negative untreated metastatic TNBC, comparing magrolimab + nab-paclitaxel/paclitaxel versus nab-paclitaxel/paclitaxel alone[1][8]. - **Cohort 2**: Includes patients with metastatic TNBC who have received one prior line of therapy in the advanced setting, a taxane in the neoadjuvant/adjuvant or metastatic setting, and, if PD-L1+, an immune checkpoint inhibitor[1]. The study includes both safety run-in and Phase 2 portions. In the safety run-in for Cohort 1, magrolimab is administered intravenously with a 1-mg/kg priming dose on day 1 of cycle 1 (to mitigate on-target anemia), followed by 30 mg/kg on specific days in subsequent cycles[1]. ## Development Status This combination therapy is currently in Phase 2 clinical trials for metastatic triple-negative breast cancer. The study is sponsored by Gilead Sciences, Inc. and is expected to run for approximately 2 years and 5 months[5]. The primary endpoints include progression-free survival for Phase 2 Cohort 1 and confirmed objective response rate for Safety Run-in Cohort 2 and Phase 2 Cohort 2[8].